Alspaugh Jonathan's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Aug 18, 2021
- Accession no.
- 0001209191-21-052272
- Filed
- Aug 18, 2021
- Trade date
- Aug 16-18, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $262.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Alspaugh JonathanCIK 0001868112 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2021 | Common Stock | PPurchaseAcquired | +9,780 | $6.37 | +$62,298.6 | 9,780 | Direct | |
| Aug 17, 2021 | Common Stock | PPurchaseAcquired | +23,392 | $6.50 | +$152,048 | 33,172 | Direct | |
| Aug 18, 2021 | Common Stock | PPurchaseAcquired | +7,200 | $6.72 | +$48,384 | 40,372 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.